Biocomposites Lands Joint Investment from TA Associates and Novo Holdings
Deal News | Mar 04, 2025 | Goodwin
TA Associates, a leading global private equity firm, has made a joint investment with Novo Holdings in the international medical devices company Biocomposites. TA, which had been Biocomposites' majority shareholder since 2017, will reinvest in the company alongside Novo Holdings and Biocomposites’ management. This partnership gives TA and Novo Holdings shared control of Biocomposites. With TA’s backing since 2017, Biocomposites has experienced significant growth, marked by a threefold revenue increase, geographic expansion, and product diversification. Partnered with Novo Holdings' new investment, Biocomposites aims to further its global reach and advance its innovative product pipeline. TA Associates, founded in 1968, focuses on high-growth investments in various sectors and has raised $65 billion in capital. Biocomposites specializes in infection management products for bone and soft tissue, operating globally. Novo Holdings manages the Novo Nordisk Foundation’s assets, investing with a focus on health improvement and sustainability, and has stakes in numerous life science companies. Legal advisory was provided by Goodwin’s team led by Arvin Abraham.
Sectors
- Private Equity
- Healthcare
- Investment Management
Geography
- United Kingdom – Biocomposites is based in Keele, UK, marking it as a significant geography in the transaction.
- Global – Both TA Associates and Novo Holdings have global operations, and Biocomposites has a global footprint with operations in several countries.
Industry
- Private Equity – TA Associates is involved in the transaction as a private equity firm, partnering with Novo Holdings to invest in Biocomposites.
- Healthcare – Biocomposites operates in the medical devices sector, specifically focusing on products for infection management in bone and soft tissue.
- Investment Management – Novo Holdings is an investment and holding company involved in the transaction to acquire joint control of Biocomposites.
Financials
- – The article does not disclose the financial terms of the investment in Biocomposites.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TA Associates | Investor | Company | A leading global private equity firm focused on scaling growth in profitable companies, invested in Biocomposites. |
| Novo Holdings | Investor | Company | A holding and investment company responsible for managing the assets of the Novo Nordisk Foundation, has invested in Biocomposites. |
| Biocomposites | Target Company | Company | An international medical devices company focused on infection management in bone and soft tissue. |
| Goodwin | Legal Advisor | Company | The law firm that provided legal advisory services for the transaction involving TA Associates and Novo Holdings. |